Masoud Sadeghzadeh

Dr. Masoud Sadeghzadeh

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 June 2013 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MSMasoud Sadeghzadeh
Masoud Sadeghzadeh
SSShahab Sheibani
Shahab Sheibani
MGMehdi Ghandi
Mehdi Ghandi
FDFariba Johari Daha
Fariba Johari Daha
MAMassoud Amanlou
Massoud Amanlou
ABAbolfazl Hasani Bozcheloie
Abolfazl Hasani Bozcheloie

5 November 2011 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
MGMehdi Ghandi
Mehdi Ghandi
ABAbolfazl Hasani Bozcheloei
Abolfazl Hasani Bozcheloei
SNSeyed Hadi Nazari
Seyed Hadi Nazari
MSMasoud Sadeghzadeh
Masoud Sadeghzadeh

13 October 2014 in Journal of Heterocyclic Chemistry
Verified
Journal Article
Closed access
PDF file
MGMehdi Ghandi
Mehdi Ghandi
MKMaryam Asle Kia
Maryam Asle Kia
MSMasoud Sadeghzadeh
Masoud Sadeghzadeh
ABAbolfazl Hasani Bozcheloei
Abolfazl Hasani Bozcheloei
Maciej KubickiMaciej Kubicki
Maciej Kubicki

1 June 2016 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
MGMehdi Ghandi
Mehdi Ghandi
FSFatemeh Sherafat
Fatemeh Sherafat
MSMasoud Sadeghzadeh
Masoud Sadeghzadeh
BABehrouz Alirezapour
Behrouz Alirezapour

14 May 2020 in Molecules
Verified
Journal Article
Open access
PDF file
MSMasoud Sadeghzadeh
Masoud Sadeghzadeh
Barbara WenzelBarbara Wenzel
Barbara Wenzel
Daniel GuendelDaniel Guendel
Daniel Guendel
WDWinnie Deuther-Conrad
Winnie Deuther-Conrad
Magali ToussaintMagali Toussaint
Magali Toussaint
PBPeter Brust
Peter Brust
Monocarboxylate transporters 1-4 (MCT1-4) are involved in several metabolism-related diseases, especially cancer, providing the chance to be considered as relevant targets for diagnosis and therapy. [18F]FACH was recently developed and showed very promising preclinical results as a potential positron emission tomography (PET) radiotracer for imaging of MCTs. Given that [18F]FACH did not show high blood-brain barrier permeability, the current work is aimed to investigate whether more lipophilic analogs of FACH could improve brain uptake for imaging of gliomas, while retaining binding to MCTs. The 2-fluoropyridinyl-substituted analogs 1 and 2 were synthesized and their MCT1 inhibition was estimated by [14C]lactate uptake assay on rat brain endothelial-4 (RBE4) cells. While compounds 1 and 2 showed lower MCT1 inhibitory potencies than FACH (IC50 = 11 nM) by factors of 11 and 25, respectively, 1 (IC50 = 118 nM) could still be a suitable PET candidate. Therefore, 1 was selected for radiosynthesis of [18F]1 and subsequent biological evaluation for imaging of the MCT expression in mouse brain. Regarding lipophilicity, the experimental log D7.4 result for [18F]1 agrees pretty well with its predicted value. In vivo and in vitro studies revealed high uptake of the new radiotracer in kidney and other peripheral MCT-expressing organs together with significant reduction by using specific MCT1 inhibitor α-cyano-4-hydroxycinnamic acid. Despite a higher lipophilicity of [18F]1 compared to [18F]FACH, the in vivo brain uptake of [18F]1 was in a similar range, which is reflected by calculated BBB permeabilities as well through similar transport rates by MCTs on RBE4 cells. Further investigation is needed to clarify the MCT-mediated transport mechanism of these radiotracers in brain.